Central nervous system involvement in adult patients with diffuse large B-cell lymphoma: Influence of rituximab

被引：2
作者：
Cao, Bing [1 ,2 ]
Zhou, Xiaoyan [2 ,3 ]
Ji, Dongmei [1 ,2 ]
Cao, Junning [1 ,2 ]
Guo, Ye [1 ,2 ]
Zhang, Qunling [1 ,2 ]
Wu, Xianghua [1 ,2 ]
Li, Junmin [4 ]
Wang, Jianmin [5 ]
Chen, Fangyuan [4 ]
Wang, Chun [6 ]
Zou, Shanhua [7 ]
Hong, Xiaonan [1 ,2 ]
机构：
[1] Fudan Univ, Dept Med Oncol, Shanghai Canc Ctr, Shanghai 200032, Peoples R China
[2] Fudan Univ, Dept Oncol, Shanghai Med Coll, Shanghai 200032, Peoples R China
[3] Fudan Univ, Dept Pathol, Shanghai Canc Ctr, Shanghai 200032, Peoples R China
[4] Shanghai Jiao Tong Univ, Dept Hematol, Ruijin Hosp, Shanghai 200030, Peoples R China
[5] Second Mil Med Univ, Dept Hematol, Changhai Hosp, Shanghai, Peoples R China
[6] Shanghai Jiao Tong Univ, Dept Hematol, Peoples Hosp 1, Shanghai 200030, Peoples R China
[7] Fudan Univ, Dept Hematol, Zhongshan Hosp, Shanghai 200032, Peoples R China
来源：
ONCOLOGY LETTERS | 2012年 / 4卷 / 03期
关键词：
central nervous system; diffuse large B-cell lymphoma; rituximab; ANTI-CD20 ANTIBODY RITUXIMAB; CHEMOTHERAPY PLUS RITUXIMAB; RANDOMIZED CONTROLLED-TRIAL; ELDERLY-PATIENTS; CHOP CHEMOTHERAPY; CNS LYMPHOMA; RISK-FACTORS; RICOVER-60; RELAPSE;
D O I：
10.3892/ol.2012.755
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone)-like chemotherapy, in combination with rituximab (R-CHOP-like), improves outcome in patients with diffuse large B-cell lymphoma (DLBCL). We aimed to investigate the impact of rituximab on central nervous system (CNS) disease in adult patients. We studied 315 patients (aged 18-60 years old) from six hospitals between July 2003 and May 2008. All patients received CHOP-like (n=165) or R-CHOP-like (n=150) regimen every 3 weeks. With a median follow-up of 3.69 years, 10 patients (3.17%) developed CNS disease. The cumulative risk of CNS occurrence was not significantly different between the two treatment groups (P=0.871). We conclude that the addition of rituximab did not reduce the risk of CNS disease in adult patients with DLBCL.
引用
收藏
页码：541 / 545
页数：5
相关论文
共 50 条
  • [1] Secondary central nervous system involvement in 599 patients with diffuse large B-cell lymphoma: are there any changes in the rituximab era?
    Deng, Lijuan
    Song, Yuqin
    Zhu, Jun
    Zheng, Wen
    Wang, Xiaopei
    Xie, Yan
    Lin, Ningjing
    Tu, Meifeng
    Ping, Lingyan
    Ying, Zhitao
    Liu, Weiping
    Zhang, Chen
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2013, 98 (06) : 664 - 671
  • [2] Central nervous system involvement in diffuse large B-cell lymphoma
    Yamamoto, Wataru
    Tomita, Naoto
    Watanabe, Reina
    Hattori, Yukako
    Nakajima, Yuki
    Hyo, Rie
    Hashimoto, Chizuko
    Motomura, Shigeki
    Ishigatsubo, Yoshiaki
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2010, 85 (01) : 6 - 10
  • [3] The addition of rituximab reduces the incidence of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma
    Mitrovic, Zdravko
    Bast, Martin
    Bierman, Philip J.
    Bociek, Robert G.
    Vose, Julie M.
    Chan, Wing C.
    Armitage, James O.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 157 (03) : 401 - 403
  • [4] Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma
    Kim, Seok Jin
    Oh, Sung Yong
    Kim, Jin Seok
    Kim, Hawk
    Lee, Gyeong-Won
    Won, Jong Ho
    Shin, Ho Jin
    Yang, Deok Hwan
    Choi, Chul Won
    Park, Jinny
    Kim, Won Seog
    Suh, Cheolwon
    ANNALS OF HEMATOLOGY, 2011, 90 (05) : 539 - 546
  • [5] Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era
    Tomita, Naoto
    Yokoyama, Masahiro
    Yamamoto, Wataru
    Watanabe, Reina
    Shimazu, Yutaka
    Masaki, Yasufumi
    Tsunoda, Saburo
    Hashimoto, Chizuko
    Murayama, Kayoko
    Yano, Takahiro
    Okamoto, Rumiko
    Kikuchi, Ako
    Tamura, Kazuo
    Sato, Kazuya
    Sunami, Kazutaka
    Shibayama, Hirohiko
    Takimoto, Rishu
    Ohshima, Rika
    Hatta, Yoshihiro
    Moriuchi, Yukiyoshi
    Kinoshita, Tomohiro
    Yamamoto, Masahide
    Numata, Ayumi
    Ishigatsubo, Yoshiaki
    Takeuchi, Kengo
    CANCER SCIENCE, 2012, 103 (02) : 245 - 251
  • [6] Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era
    Kumar, Anita
    Vanderplas, Ann
    LaCasce, Ann S.
    Rodriguez, Maria A.
    Crosby, Allison L.
    Lepisto, Eva
    Czuczman, Myron S.
    Nademanee, Auayporn
    Niland, Joyce
    Gordon, Leo I.
    Millenson, Michael
    Zelenetz, Andrew D.
    Friedberg, Jonathan W.
    Abel, Gregory A.
    CANCER, 2012, 118 (11) : 2944 - 2951
  • [7] Central nervous system involvement in diffuse large B-cell lymphoma: an analysis of risks and prevention strategies in the post-rituximab era
    Fletcher, Christopher D.
    Kahl, Brad S.
    LEUKEMIA & LYMPHOMA, 2014, 55 (10) : 2228 - 2240
  • [8] Secondary central nervous system involvement in 599 patients with diffuse large B-cell lymphoma: are there any changes in the rituximab era?
    Lijuan Deng
    Yuqin Song
    Jun Zhu
    Wen Zheng
    Xiaopei Wang
    Yan Xie
    Ningjing Lin
    Meifeng Tu
    Lingyan Ping
    Zhitao Ying
    Weiping Liu
    Chen Zhang
    International Journal of Hematology, 2013, 98 : 664 - 671
  • [9] Central nervous system prophylaxis in diffuse large B-cell lymphoma
    Zahid, Mohammad Faizan
    Khan, Nadia
    Hashmi, Shahrukh K.
    Kizilbash, Sani Haider
    Barta, Stefan K.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2016, 97 (02) : 108 - 120
  • [10] Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy
    Villa, D.
    Connors, J. M.
    Shenkier, T. N.
    Gascoyne, R. D.
    Sehn, L. H.
    Savage, K. J.
    ANNALS OF ONCOLOGY, 2010, 21 (05) : 1046 - 1052
12345